ArticleAmerican journal of translational research2026
Model-guided dose optimization of cefoperazone-sulbactam and levofloxacin for pneumonia and urinary tract infections in patients with hepatic dysfunction.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDose optimization of ceftazidime-sulbactam (CFP-SUL) and levofloxacin (LVFX) for pneumonia and urinary tract infections in patients with hepatic insufficiency.
methodsA total of 100 patients were recruited from the First People's Hospital of Chun'an County and Hanchuan People's Hospital between January 2018 and November 2024. It compared two groups, with primary endpoints (successful intention-to-treat, treatment failure, 7-day clinical cure rate, time to cure, symptom improvement), secondary endpoints (reasons for treatment failure, free time (fT) > minimal inhibitory concentration (MIC) target achievement, adverse event incidence), and performed a subgroup analysis.
resultsCFP-SUL's MIC values against bacterial isolates ranged from 16 to 256 mg/L, with 36.70% resistant and 63.60% susceptible. LVFX's MIC ranged from 0.25 to 64 mg/L. Compared with the standard-dose group, the model-guided group showed a significantly higher success rate (98.00% vs. 80.00%), a greater proportion of 7-day clinical cures (68.00% vs. 54.00%), a higher rate of achieving the CFP-SUL pharmacodynamic target (86.00% vs. 70.00%), and a higher rate of achieving targets for both drugs (74.00% vs. 61.00%,
conclusionModel-guided CFP-SUL with LVFX dose optimization in pneumonia with urinary tract infection and hepatic dysfunction improves patient acceptance of intention-to-treat and treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.